Search
for
Sort by
Research 31–60 of 1000+
- 12. Cancer
- Long-term opioid ADR management in cancer patients
- The efficacy of an adjuvant norethisterone (jenapharm) therapy in endometrial cancer
- Context-dependent effect of sPLA2-IIA induced proliferation on murine hair follicle stem cells and human epithelial cancer
- Diabetes, ovarian tumor, hyperparathyroidism, and papillary cancer: A chance association?
- Tobacco and the skin
- Safety of testosterone treatment in postmenopausal women
- Management of congenital ichthyoses: European guidelines of care, part two
- Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
- Dermatological manifestations in patients with chronic kidney disease
- Complications of Self‐Injected Facial Fillers: A Treatment Conundrum in the UK
- Smoking and the skin
- Utilization of Telemedicine in the U.S. Military in a Deployed Setting
- Mucocutaneous manifestations in children with human immunodeficiency virus infection
- Hirsutism and virilization
- Diagnosis and Management of Polycystic Ovary Syndrome (PCOS)
- Hair Changes due to Drugs
- Controversies in Polycystic Ovary Syndrome
- New insights into the role of Runx1 in epithelial stem cell biology and pathology
- Venous thromboembolism and women's health
- Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study
- A Review of hormone-based therapies to treat adult acne vulgaris in women
- Síndrome de ovarios poliquísticos Polycystic ovary syndrome
- Effect of contraceptives on the skin.
- Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- Oral Presentation Abstracts
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma
- Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
- Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line